CA
FATE icon

CastleArk Alternatives’s Fate Therapeutics FATE Stock Holding History

CastleArk Alternatives’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-52,908
Closed -$3.14M – 111
2021
Q3 		$3.14M Buy
+52,908
New +$4.15M 0.12% 160

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

CastleArk Alternatives's FATE Position: Q4 2021 in Review

CastleArk Alternatives sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 52,908 shares — an estimated $3.14M sold.

CastleArk Alternatives first reported a position in FATE in Q3 2021 and held it in 1 quarter. The position peaked at $3.14M in Q3 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • CastleArk Alternatives reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 52,908 Fate Therapeutics shares in Q4 2021, an estimated $3.14M.
  • CastleArk Alternatives first reported a position in Fate Therapeutics in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's Fate Therapeutics position peaked at $3.14M in Q3 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.